The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2023

Filed:

Jan. 23, 2020
Applicant:

Allegro Pharmaceuticals, Llc, San Juan Capistrano, CA (US);

Inventors:

Michael John Mackel, Portland, OR (US);

John Y. Park, Santa Ana, CA (US);

Hampar L. Karageozian, San Juan Capistrano, CA (US);

Vicken H. Karageozian, San Juan Capistrano, CA (US);

Assignee:

Allegro Pharmaceuticals, LLC, San Juan Capistrano, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 5/09 (2006.01); A61K 47/64 (2017.01); A61K 51/08 (2006.01); C07K 7/06 (2006.01); C07K 7/64 (2006.01); A61K 9/08 (2006.01); A61K 38/17 (2006.01); A61K 51/06 (2006.01); A61L 26/00 (2006.01); A61L 27/00 (2006.01); A61L 27/22 (2006.01); A61L 31/04 (2006.01); G01N 1/00 (2006.01); A61K 38/06 (2006.01); A61K 38/08 (2019.01); A61K 38/12 (2006.01); A61K 39/395 (2006.01); A61K 9/06 (2006.01);
U.S. Cl.
CPC ...
C07K 5/0817 (2013.01); A61K 9/08 (2013.01); A61K 38/06 (2013.01); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 38/1709 (2013.01); A61K 39/3955 (2013.01); A61K 47/64 (2017.08); A61K 51/065 (2013.01); A61K 51/082 (2013.01); A61K 51/088 (2013.01); A61L 26/00 (2013.01); A61L 27/00 (2013.01); A61L 27/227 (2013.01); A61L 31/043 (2013.01); C07K 7/06 (2013.01); C07K 7/64 (2013.01); G01N 1/00 (2013.01); A61K 9/06 (2013.01); A61L 2300/252 (2013.01);
Abstract

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH—SOH)COOH or Arg-Gly-NH—CH(CH—SOH)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to αβ-Integrin, αβ-Integrin and αβ-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.


Find Patent Forward Citations

Loading…